Heyholder
‹ Activism Filings

SyntekaBio,Inc. Q3 operating loss of KRW 3.7 billion on revenue of KRW 0.7 billion

SyntekaBio,Inc.· Periodic Report

AI summary · Not investment advice

In Q3, the company sold KRW 0.7 billion worth and lost KRW 3.7 billion from its main business, versus KRW 0.5 billion in sales and a KRW 2.3 billion loss a year earlier.

Operating profit · 3 months

KRW -3.7 billion

Key facts

Revenue (3 months)
KRW 689.3 million
Net income (3 months)
KRW -4.3 billion
Period
Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
Revenue (prior-year 3 months)
KRW 455.5 million
Revenue (year to date)
KRW 1.6 billion
Operating profit (prior-year 3 months)
KRW -2.3 billion
Operating profit (year to date)
KRW -9.4 billion
Net income (prior-year 3 months)
KRW -2.3 billion
Net income (year to date)
KRW -10.0 billion

Commentary

AI commentary · Not investment advice

What happened

Synteca Bio filed its quarterly report for the third quarter of 2026, on a consolidated basis. Sales for the latest 3 months were KRW 689.3 million. That is 51.3% more than the same 3 months a year earlier, when sales were KRW 455.5 million.

In the company's terms

Operating profit (profit from the core business) for the 3 months was a loss of KRW 3.67 billion. A year earlier it was a loss of KRW 2.31 billion. Net income (the final profit after taxes and other items) for the 3 months was a loss of KRW 4.30 billion. A year earlier it was a loss of KRW 2.30 billion.

What changes for shareholders

For the year to date (January 1 to September 30), sales were KRW 1.56 billion. Operating profit was a loss of KRW 9.40 billion. Net income was a loss of KRW 10.0 billion. The report lists no upcoming events.

Comments

No comments yet

Comments from shareholders will appear here.